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Abstract
The nonalcoholic fatty liver disease (NAFLD) is the liver disorder that is most com-
mon in Western countries; has a global prevalence of approximately 25%; and is strongly 
associated to obesity and metabolic syndrome. According to the Third National Health 
and Nutrition Examination Survey (NHANES III), the prevalence of NAFLD is more 
common in obese individuals with a prevalence of 39.4% than in lean individuals with 
a prevalence of 7.7%. Nonalcoholic fatty liver disease is the hepatic manifestation of the 
metabolic syndrome and is defined as the accumulation of fat in the liver. The NAFLD is 
defined by an accumulation of fat in liver with >5% of steatosis by histologic examination 
or by proton density fat fraction >5.6%. The diagnosis of NAFLD implies the exclusion of 
secondary causes like alcohol consumption. The NAFLD includes two different patho-
logical conditions with different prognosis: the nonalcoholic fatty liver (NAFL) and the 
nonalcoholic steatohepatitis (NASH), the last one has a wide spectrum of severity.
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1. Introduction
The nonalcoholic fatty liver disease is the most common liver alteration in 
the Western countries, with an incidence from the 17–46% of the adult patients 
[1]. Analysis of the Third National Health and Nutrition Examination Survey 
presented in the 2018 Annual Meeting of the American Association for the Study 
of Liver Diseases [2] demonstrated nonalcoholic fatty liver disease prevalence of 
7.7% among lean individuals vs. 39.4% among obese individuals. The prevalence of 
NAFLD among lean individuals without any components of metabolic syndrome 
was 2.2%, and no evidence of increased overall or cardiovascular-related mortal-
ity among this subgroup was found. The presence of diabetes mellitus (DM) was 
identified as independent risk factor for NAFLD in both lean and obese individuals 
in multivariate logistic regression analysis (Table 1).
The nonalcoholic fatty liver disease is defined as the accumulation of fat in the 
liver and can be considered a hepatic manifestation of the metabolic syndrome. The 
prevalence of NAFLD is 20–30% in adults and is higher in industrialized countries [3].
The screening for NAFLD in the community has been questioned for high costs of 
testing, but the progressive form of NAFLD, particularly when associated with advanced 
fibrosis, should be identified in patients at risk, because of its prognostic implications.
2. Definition of NAFLD
The NAFLD is characterized by an excessive liver fat accumulation and insulin 
resistance. Liver biopsy is the standard for diagnosis of NALFD, and it is defined by 
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the presence of more than 5% of steatosis of the hepatocytes by histologic examina-
tion or more than 5.6% assessed by proton magnetic resonance spectroscopy or 
quantitative fat/water selective magnetic resonance imaging.
The diagnosis of NAFLD implies the differentiation of two different liver dis-
orders associated to the liver fat accumulation: the nonalcoholic fatty liver and the 
nonalcoholic steatohepatitis. NAFL can be subdivided in pure steatosis and steatosis 
with mild lobular inflammation. The spectrum of the NASH has includes a wide 
range of stages from: early NASH: no or mild fibrosis (stages F0-F1), fibrotic NASH; 
that includes significant (F2) or advanced (F3) fibrosis, NASH-cirrhosis (F4), and 
hepatocellular carcinoma (Table 2).
The NAFLD also called primary NALFD is associated with risk factors and com-
ponents of metabolic syndrome, like waist circumference >94 cm in men or >80 in 
women, arterial pressure >130/85 mmHg or treated for hypertension, serum triacylg-
lycerols >150 mg/dL, and HDL cholesterol <40 mg/dL in men or <50 mg/dL in women.
The screening for metabolic syndrome independent of liver enzymes in all the 
patients with liver steatosis is recommended, and, because the nonalcoholic fatty 
liver disease is the main reason of unexpected elevated liver enzymes, the patients 
with persistently high elevation of liver enzymes must be screened. The screening 
of NAFLD with liver enzymes and USG in the patients with obesity or metabolic 
syndrome is also recommended.
3. Pathogenesis
The high-calorie diet with an excess of saturated fats and refined carbohydrates 
has been associated with weight gain and obesity and more recently with NAFLD 
[4, 5]. The “multiple hit” hypothesis considers multiple insults acting together on 
NAFL NASH
Pure steatosis Early NASH (F0–F1) no or mild fibrosis





NAFLD prevalence, % Lean subjects  
(n = 3242)
Obese subjects (n = 2592)
Male Female Male Female
Total 7.32 7.54 50.48* 35.2
Metabolically normal 4.39 7.12 23.89 15.14
DM + hypertension/hyperlipidemia 15.32 23.65 65.61 49.34
Hypertension + hyperlipidemia, only 12.76* 0.92 32.26 25.7
DM, only 15.01 6.50 5.32 57.96*
Hypertension, only 5.17 1.54 29.76 33.48
Hyperlipidemia, only 7.47 9.28 43.91* 20.75
*P < .05 for difference in men vs. women within lean or obese subsets.
Table 1. 
Prevalence of NAFLD according to features of metabolic syndrome in lean and obese subjects in NANHES III.
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genetically predisposed subjects to induce NAFLD and provide a more accurate 
explanation of NAFLD pathogenesis [6].
Dietary habits and genetic and environmental factors can lead to insulin resis-
tance, obesity with adipocyte proliferation, and changes in the gut microbiota. The 
insulin resistance is a key factor in the pathogenesis of NAFLD; the insulin resis-
tance results in a hepatic de novo lipogenesis and impaired inhibition of adipose 
tissue lipolysis, with consequent increased flux of fatty acids to the liver [7]. Insulin 
resistance also promotes adipose tissue dysfunction that results in an impaired 
secretion of adipokines and inflammatory cytokines [8] (Figure 1).
Genetic factors and epigenetic changes, in predisposed individuals, affect 
hepatocyte fat content and contribute to create an inflammatory environment in 
the liver with possible progression to hepatocellular death mediated for both direct 
toxicity and apoptosis activating mechanisms, activation of hepatic stellate cells, 
and deposition of fibrous matrix.
Altered microbiota in the gut leads to the fatty acid accumulation in the small 
bowel, increased permeability and absorption of fatty acids, and raised circulating 
levels of molecules which contribute to the activation of inflammatory pathways 
and release of proinflammatory cytokines [9].
Figure 1. 
Multiple hit theory of pathogenesis of NAFLD.
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Genetic variants, especially in the form of single nucleotide polymorphisms, 
influence hepatic fatty acids flux, oxidative stress, response to endotoxins, and 
cytokine production and activity and are determinants of NAFLD development and 
progression. Epigenetic modifications are defined as stable changes which do not 
alter the basic DNA sequences at transcriptional level, such as histone modifica-
tions, DNA methylation, and activity of microRNAs, and these changes contribute 
to a high degree of developmental and environmentally driven plasticity in the cell 
homeostasis [10, 11].
Genotyping may be considered in selected patients and clinical studies but is not 
recommended routinely. The carriers of the PNPLA3 I148M and the TM6SF2 E167K 
genotypes have a higher liver fat content and increased risk of NASH. The NAFLD 
due to these variants is not systematically associated with features of insulin 
resistance.
4. Diagnosis
The standard procedure for the diagnosis of NASH is the liver biopsy and is the 
only procedure that can differentiate the NAFL from NASH, despite limitations due 
to sampling variability [12].
The histologic NAFL features include steatosis alone, steatosis with lobular or 
portal inflammation, without ballooning, or steatosis with ballooning but without 
inflammation.
For evaluation of severity of the disease, the NAFLD Activity Score (NAS) 
scoring system can be used; this score should not be used for diagnosis. This score 
is correlated with homeostasis model assessment of insulin resistance (HOMA-IR) 
and the aminotransferase level [13].
Noninvasive diagnostic procedures must be considered in primary care settings; 
they identify the risk of NAFLD among individuals with increased metabolic risk; in 
secondary and tertiary care settings, they identify those with worse prognosis; moni-
tor disease progression; and predict response to therapeutic interventions.
When NAFLD is suspected as the primary disease or as a coexisting condition, 
steatosis should be documented. The presence of NASFLD also predicts cardiovas-
cular events, arterial hypertension, and diabetes mellitus. The quantification of fat 
content is not of interest, in clinical practice, except for the evaluation of treatment 
efficacy, and is therefore not generally recommended. Steatosis of the liver should 
be documented by ultrasonography, because it is a cheaper and more available 
method than MRI. US has limited sensitivity and does not reliably detect steatosis 
when <20% [14, 15].
US is the preferred first-line diagnostic procedure for imaging of NAFLD, as 
it provides additional diagnostic information. A quantitative estimation of liver 
fat can only be obtained by 1H-MRS. This technique is of value in clinical trials 
and experimental studies but is expensive and not recommended in the clinical 
setting.
The diagnosis of NASH implicates closer follow-up, provides important 
prognostic information, and indicates an increased risk of fibrosis progression, 
cirrhosis, and possibly hepatic comorbidities. It may also prompt possibly a greater 
need for more intensive therapy. Clinical, biochemical, or imaging measures cannot 
distinguish NASH from steatosis [16, 17].
NASH must be diagnosed by a liver biopsy showing steatosis, hepatocyte bal-
looning, and lobular inflammation. Biomarkers and scores of fibrosis, as well as 
transient elastography, are acceptable noninvasive procedures for the identification 
of cases at low risk of advanced fibrosis/cirrhosis.
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5. Metabolic disorders linked to NAFLD
5.1 Obesity
Insulin resistance has been associated with NAFLD, not only in the liver but also 
in adipose tissues and muscle and also with the metabolic syndrome. The meta-
bolic syndrome is defined as the cluster of any three of the following five features: 
impaired fasting glucose or type 2 diabetes mellitus, hypertriglyceridemia, low 
high-density lipoprotein (HDL) cholesterol, increased waist circumference, and 
high blood pressure [18].
Obesity is the major phenotype and risk condition for NAFLD, driven by insulin 
resistance, and increases the risk of advanced disease. Most lean persons with 
NAFLD display insulin resistance and altered body fat distribution even though 
they have less severe metabolic disturbance than overweight NAFLD.
5.2 Diabetes mellitus
Type 2 diabetes mellitus patients are insulin resistant, often obese, dyslipidemic, 
display increased liver enzymes, and tend to accumulate hepatic fat, without rela-
tion with the body mass index [19–21].
In persons with NAFLD, screening for diabetes is mandatory, and in patients with 
type 2 diabetes mellitus, the presence of NAFLD should be looked for irrespective of 
liver enzyme levels, since those patients are at high risk of disease progression.
5.3 Cardiovascular disease
Atherogenic lesions such as increased carotid intima-media thickness, coro-
nary artery and abdominal aortic and aortic valve calcifications, and endothelial 
dysfunction are more common in NAFLD. The prevalence and incidence of car-
diovascular disease is higher in NAFLD than in matched controls and driven by the 
association between NAFLD and metabolic syndrome components. In most studies, 
biochemical markers of atherosclerosis or inflammation and increased levels of 
procoagulant/prothrombotic factors are more common in NAFLD than in persons 
without steatosis. They are largely independent of traditional risk factors, duration 
of diabetes, glycemic control, drug treatment, and metabolic syndrome compo-
nents. The consensus is that cardiovascular disease should be identified in NAFLD 
regardless of the presence of traditional risk factors. Conversely NAFLD screening 
should be performed in persons at high CVD risk [22–24].
5.4 Natural history
In general, NAFLD is a slowly progressive disease, but in 20% of cases fibrosis 
rapidly progresses. The rate of progression corresponds to one fibrosis stage every 
14 years in NAFL and every 7 years in NASH and is doubled by arterial hyperten-
sion. Compared with the general population, NASH is associated with an increased 
standardized mortality ratio. US-diagnosed NAFLD is not associated with increased 
mortality, presumably because progression to NASH and fibrosis is rare for steatosis 
alone (Figure 2) [25–27].
Metabolic reprogramming for adaptation to the local environment has been 
recognized as a hallmark of cancer. Although alterations in fatty acid metabolism 
in cancer cells have received less attention compared to other metabolic alterations 
such as glucose or glutamine metabolism, recent studies have uncovered the impor-
tance of lipid metabolic reprogramming in carcinogenesis.
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Obesity and nonalcoholic steatohepatitis (NASH) are well-known risk factors 
of hepatocellular carcinoma (HCC), and individuals with these conditions exhibit 
an increased intake of dietary FAs accompanied by enhanced lipolysis of visceral 
adipose tissue due to insulin resistance, resulting in enormous exogenous fatty acid 
supplies to hepatocytes via the portal vein and lymph vessels. However, the way in 
which HCC cells adapt to such a condition and exploit it to aid their progression is 
not understood. In addition, accumulating evidence supports the importance of 
lipid metabolic reprogramming in various situations of hepatocarcinogenesis.
5.5 Treatment
Successful treatment of NASH should improve outcomes. The resolution of 
the histological lesions defining NASH is now accepted as a surrogate end point, 
particularly in clinical trials. Few well-designed randomized controlled trials are 
available, with improvement/regression of hepatic necroinflammation and/or 
fibrosis as primary outcomes.
5.6 Diet and lifestyle changes
Epidemiological evidence suggests a tight relationship between unhealthy 
lifestyle and NAFLD, which makes lifestyle correction mandatory in all patients. 
Relatively small amounts of weight loss reduce liver fat and improve hepatic insulin 
resistance [28].
For the patients with NAFLD, structured programs for lifestyle changes toward 
healthy diet and habitual physical exercise  are recommended. The counseling for 
healthy diet and physical activity is the election therapy in patients without NASH 
or fibrosis and with no pharmacotherapy for their liver condition. In overweight 
or obese NAFLD, weight loss, with a target of 7–10% of the basal weight, is recom-
mended; this results in histology and liver enzyme improvement. Dietary recom-
mendations should consider the caloric restriction and the exclusion of processed 
food and food and beverages high in added fructose which are NAFLD-promoting 
components. A macronutrient composition is recommended according to the 
Figure 2. 
Natural history of NAFLD. HCC denotes hepatocellular carcinoma.
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Mediterranean diet. Both resistance training and aerobic exercise effectively reduce 
the amount of fat in the liver. The training must be maintained in the long-term 
and then is recommended that the choice of training should be tailored based on 
patients’ preferences.
5.7 Drug therapy
Pharmacotherapy should be reserved for patients with NASH, particularly 
for those with significant fibrosis (stage F2 and higher). Patients with less severe 
disease, but at high risk of disease progression, could also be candidates to prevent 
disease progression.
While no firm recommendations can be made, pioglitazone or vitamin E or their 
combination could be used for NASH.
The optimal duration of therapy is unknown; in patients with increased ALT 
at baseline, after 6 months of therapy, treatment should be stopped if there is no 
reduction in aminotransferases; no recommendations can be made in patients with 
normal ALT at baseline.
The statins have not been showed benefit in liver harm in patients with NAFLD, 
but may be confidently used to reduce LD cholesterol and prevent cardiovascular 
risk. There is not data to support the use of n-3 polyunsaturated fatty acids specifi-
cally for NASH, but reduce both liver and plasma lipids [29].
By improving obesity and diabetes, bariatric surgery reduces liver fat and is 
likely to reduce NASH progression; prospective data have shown an improvement in 
all histological lesions of NASH, including fibrosis [29].
5.8 Drugs in study
In the 2018 Annual Meeting of the American Association for the Study of Liver 
Diseases, phase II data in therapies with drugs for NAFLD and NASH were pre-
sented (Table 3).
5.9 Farnesoid X receptor agonists
Farnesoid X receptors (FXRs) are nuclear hormone receptors expressed in high 
amounts in body tissues that participate in bilirubin metabolism including the liver, 
Agent MOA N Study population
GS-9674 FXR agonist 140 NASH
Obeticholic acid FXR agonist 84 NASH, fibrosis
Tropifexor FXR agonist 198 NASH
NGM282 FGF19 analogue 38, 85 NASH
MGL-3196 THR-β agonist 125 NASH, hepatic fat fraction ≥10%
VK2809 THR-β agonist 35 NAFLD, liver fat >8%, elevated LDL-C and TG
GS-0976 ACC inhibitor 75 NASH, no cirrhosis
Aramchol SCD1 inhibitor 247 NASH, overweight or obesity, prediabetes or 
diabetes
Semaglutide GLP-1 receptor 
agonist
957 Obesity, no diabetes
Table 3. 
Phase II Data on Investigational NAFLD/NASH Therapies Presented at AASLD 2018.
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intestines, and kidneys. Bile acids are the natural ligands of the FXRs. XRs play a 
critical role in carbohydrate and lipid metabolism and regulation of insulin sensitiv-
ity. FXRs also modulate live growth and regeneration during liver injury.
The farnesoid X receptor agonist GSK-9674 was compared with placebo at doses 
of 30 and 100 mg and showed ≥30% relative reduction in liver fat, and markers of 
fibrosis also improved [30].
Obeticholic acid (OCA) is a semisynthetic bile acid analogue which has the 
chemical structure 6α-ethyl-chenodeoxycholic acid. The natural bile acid, cheno-
deoxycholic acid, was identified in 1999 as the most active physiological ligand for 
the farnesoid X receptor, which is involved in many physiological and pathological 
processes. In a double-blind, placebo-controlled, phase II study, the OCA was com-
pared with placebo; at week 16, patients with vs. without cirrhosis (F4 vs. F1–F3) 
showed no trend for differences in ALT, bilirubin, platelets, and INR [31].
The FLIGHT study on tropifexor (TXR), a three-part randomized, placebo-
controlled, double-blind, dose-ranging phase IIb study in adults with NASH, weigh-
ing 40–150 kg with liver fat ≥10%, showed reduction in liver fat, ALT, and GGT 
compared with placebo [32].
5.10 Fibroblast growth factor (FGF) analogues
NGM282 is a non-tumorigenic analogue of human FGF19 demonstrating 
significant reductions in hepatic steatosis, liver transaminases, and fibrosis mark-
ers after 12 weeks of treatment at doses of 3 and 6 mg. The use of NGM282 for 
12 weeks at doses of 1 and 3 mg showed clinically meaningful improvements in 
fibrosis in NASH patients and in all components of the NASH, and this was pre-
ceded by rapid and significant improvements in liver transaminases and imaging-
based parameters [33].
5.11 Tyroid hormone receptor beta (THR-β)
In a randomized, multicenter, placebo-controlled phase IIa study, at Week 
12 a higher proportion of patients with liver fat >30% compared with placebo is 
shown [34].
MGL-3196 is a liver-directed, orally active, highly selective THR-β agonist which 
may reduce lipotoxicity in NASH by increasing hepatic fat metabolism. At Week 36, 
MGL-3196 treatment compared with placebo resulted in significant and sustained 
reductions in hepatic fat on MRI-PDFF, liver enzymes, fibrosis biomarkers, ath-
erogenic lipids, and improvement in NASH on liver biopsy. In the patients treated 
with MGL‐3193 was observed ≥30% fat reduction (MRI-PDFF) at Week 12 and 
improved NASH histologic response at Week 36 were predicted [35].
5.12 Acetyl-CoA carboxylase (ACC) inhibitor
Elevated plasma levels of medium- and long-chain acylcarnitines are markers 
of impaired mitochondrial beta oxidation of fatty acids. GS-0976 inhibits cyto-
plasmic ACC1 and mitochondrial ACC2 thereby reducing fatty acid synthesis and 
augmenting beta oxidation, respectively. NASH patients who responded to GS-0976 
demonstrated a reduction in plasma acylcarnitine species with reduction of liver fat 
by MRI-PDFF also. This effect is consistent with an improvement in the efficiency 
of mitochondrial beta oxidation. The reductions in plasma acylcarnitine species 
provide further evidence to support, in patients with NASH for the therapeutic 
targeting of ACC1 and ACC2 [36].
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5.13 Stearoyl-coenzyme A desaturase 1 (SCD-1) modulator
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conju-
gate, inducing beneficial modulation of intrahepatic lipid metabolism. The ARREST 
study enrolled 247 NASH patients who were overweight/obese and had prediabetes 
or diabetes with HbA1C at baseline of 6.6%. More than 50% were hypertensive and 
had dyslipidemia. Baseline histology demonstrated a population with advanced 
disease, with 60% having stage 2 and 3 fibrosis and 70% having NAS ≥ 5.
The study ARREST, is a randomized, global phase IIb study with aramchol in 
patients with NASH and diabetes or prediabetes, compared aramchol at doses of 400 
and 600 mg versus placebo, in the aramchol patients the proportion with >5% of 
reduction in liver fat by MRI, the resolution of NASH than in the placebo group [37].
5.14 Glucagon-like peptide type 1 (GLP-1) receptor agonist
The glucagon-like peptide 1 analogues semaglutide and liraglutide improve 
glycemic control and reduce elevated liver enzymes in subjects with type 2 diabe-
tes and reduce body weight in subjects with or without diabetes. Semaglutide at 
doses of 0.2–0.4 mg daily reduced ALT in subjects with obesity and high ALT to an 
extent that was broadly comparable across weight loss categories and resulted after 
52 weeks in dose-related ALT normalization in up to 46% of subjects. These data 
suggest a potential role for semaglutide in the treatment of NAFLD with elevated 
liver enzymes [38].
5.15 Bariatric surgery
Medical therapy, including the newly available drugs, has only limited effects 
and does neither influence survival or the development of complications or the pro-
gression of NASH to liver cirrhosis or the development of hepatocellular carcinomas 
in NASH. Importantly, even existing diabetic complications such as nephropathy as 
well as the features of NASH can be reversed by metabolic surgery.
Metabolic surgery is a very effective treatment for NAFLD in general, but in 
particular for NASH, the beneficial and significant changes in steatosis and NAS 
after metabolic surgery have been shown with steatosis decreased from 60 to 
10% after surgical treatment, and the NASH diminished from 5 to 1, essentially 
normalizing the liver histology in patients with NASH. Metabolic surgery has even 
shown to reduce liver fibrosis. A meta-analysis also demonstrated this effect: each 
of the 16 studies included demonstrated a diminution of steatosis after metabolic 
surgery [39, 40].
6. Conclusions
The nonalcoholic fatty liver disease is the liver disorder most common in Western 
countries, has a global prevalence of approximately 25%, and is strongly associated 
to obesity and metabolic syndrome. Successful treatment of NASH should improve 
outcomes. Lifestyle changes are the foundation of any treatment plan and weight 
loss ≥3–10% associated with histologic improvement in NAFLD. In the guides of 
the European Association for Study of Liver disease (EASLD) and the American 
Association for the Study of Liver Disease (AASLD) is cited recommendations for 
the use of vitamin E (NASH without diabetes), pioglitazone (NASH with or without 
diabetes), and bariatric surgery.
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